Physician profile
Kevin Hur
NPI 1679996102
$13,002.30
in general payments reported to CMS, 2019-2025
15 companies · $2,211 in 2025
The $2,211 reported for 2025 was more than what 90% of Otolaryngology providers received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,072 · 2020: $338 · 2021: $101 · 2022: $5.70 · 2023: $167 · 2024: $9,108 · 2025: $2,211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $7,824 · Travel and Lodging: $2,620 · Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $7,824.00 |
| Travel and Lodging | $2,619.93 |
| Food and Beverage | $1,041.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $9,128.65 | 2024-2025 | |
| Medtronic, INC. | $1,971.92 | 2023-2025 | Propel, Fusion |
| Stryker Corporation | $414.39 | 2019-2021 | |
| Medtronic USA, INC. | $360.45 | 2019-2020 | |
| Intersect Ent, INC. | $269.68 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $203.09 | 2019-2024 | Dupixent |
| Aerin Medical INC. | $197.87 | 2025 | |
| Smith+Nephew, INC. | $166.63 | 2019 | |
| Integra Lifesciences Corporation | $126.74 | 2019 | |
| 3-D Matrix, INC. | $107.88 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.49 | 2020 | |
| Abbvie INC. | $16.81 | 2020 | |
| Neurent Medical Limited | $5.70 | 2022 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Hur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.